Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study

Table 3 Estimated caregiver productivity increase with subcutaneous versus intravenous monoclonal antibodies administration

	Under current conditions		Subcutaneous in all eligible patients^a
	Rituximab	Trastuzumab	Rituximab	Trastuzumab
In combination with chemotherapy	19.2%	9.9%	39.4%	22.5%
As maintenance therapy	17.0%	34.7%	22.9%	41.4%
Average^b	21.2%		32.5%

^aAssuming a complete conversion to SC formulations according to the approved SmPC (45% of rituximab treatments and 91% of trastuzumab treatments)
^bBased on the following assumptions: (1) the first dose of rituximab is administered IV in all patients; (2) 48% of the total number of patients have first-line follicular lymphoma and receive 8 cycles of rituximab in combination with chemotherapy and 12 as maintenance therapy, (3) 14% of the total number of patients have relapsed refractory follicular lymphoma and receive 8 cycles of rituximab in combination with chemotherapy and 8 as maintenance therapy, (4) 38% of the total number of patients have diffuse large B-cell lymphoma and receive 8 cycles of rituximab in combination with chemotherapy; (5) trastuzumab is given as first cycle loading dose in combination with chemotherapy, 7 subsequent cycles in combination with chemotherapy, and 10 cycles in maintenance therapy; a total of 18 cycles/year
SC subcutaneous, SmPC summary of product characteristics